NAI(NAII) - 2024 Q1 - Quarterly Report

Financial Performance - Net sales for the three months ended September 30, 2023, decreased by 21% to $33.97 million compared to $43.13 million in the same period in 2022[102]. - Private-label contract manufacturing sales fell by 23% to $32.19 million, primarily due to reduced orders from larger customers aiming to decrease excess inventory[90][103]. - Gross profit decreased by 42% to $3.14 million, with a gross profit margin of 9.2%, down from 12.5% in the previous year[102]. - The company reported a net loss of $0.70 million for the three months ended September 30, 2023, compared to a net income of $1.05 million in the same period last year, marking a 166% decline[102]. Cash Flow and Financial Position - Cash flows from operating activities were $4.5 million for the three months ended September 30, 2023, compared to a cash outflow of $4.6 million in the same period last year[110]. - Changes in accounts receivable used $2.7 million in cash, while changes in inventory provided $6.4 million in cash during the same period[111][112]. - As of September 30, 2023, the company had $16.7 million in cash and cash equivalents, with $14.2 million held by NAIE[116]. - The company anticipates non-compliance with covenants under the Credit Agreement in Q2 of fiscal 2024 due to reduced sales and temporary closure of the Carlsbad facility[116]. - There were no off-balance sheet debts or significant obligations that could materially affect the company's financial condition as of September 30, 2023[117]. Future Outlook - The company anticipates a net loss in the first half of fiscal 2024, with expectations of net income in the second half, resulting in an overall net loss for the fiscal year[96]. - The company is negotiating a potential revised credit facility, with no assurance of successful completion or terms[116]. - The company plans to continue investing in research and development for its SR CarnoSyn® sustained release delivery system to capitalize on growth in the Wellness and Healthy Aging markets[92]. Legal and Compliance - Legal expenses related to maintaining patents and trademarks increased to approximately $71,000 from $30,000 in the prior year[94]. - The company maintains effective disclosure controls and procedures as of September 30, 2023, as evaluated by the CEO and CFO[120]. - No changes in internal control over financial reporting occurred during the quarterly period ended September 30, 2023, that materially affected the controls[121].